

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1. (withdrawn): A method for treatment of neuropsychiatric disorders which comprises administration of a D-serine transport inhibitor at a dose sufficient to enhance NMDA receptor-mediated neurotransmission in vivo.
2. (withdrawn): The method of claim 1 wherein the disorder is associated with decreased *N*-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission.
3. (withdrawn): The method of claim 1 wherein the disorder is a psychotic disorder.
4. (withdrawn): The method of claim 3 wherein the psychotic disorder is schizophrenia.
5. (withdrawn): The method of claim 1 wherein the disorder is Alzheimer's disease, bipolar illness, depression and anxiety disorders, stroke or epilepsy.
6. (withdrawn): The method of claim 1 wherein the disorder is age associated memory impairment, closed head injury or attention deficit disorder.
7. (withdrawn): The method of claim 1 wherein such agent is administered orally.
8. (withdrawn): The method of claim 1 wherein a D-serine transport inhibitor is administered parenterally.

9. (withdrawn): A method for augmentation of *N-methyl-D*-aspartate receptor-mediated neurotransmission in vivo which comprises administration of a D-serine transport antagonist.
10. (withdrawn): The method of claim 1 or 9 wherein the antagonist is an inhibitor of D-serine transport mediated through system ASC.
11. (withdrawn): The method of claim 1 or 9 wherein the antagonist is an inhibitor of systems L, N, A or Gly.
12. (withdrawn): The method of claim 1 or 9 wherein the antagonist is an inhibitor of alanine-sensitive D-serine transport.
13. (withdrawn): The method of claim 1 or 9 where the antagonist is an inhibitor of alanine-insensitive D-serine transport.
14. (withdrawn): The method of claim 1 or 9 wherein the agent is glycyl dodecylamide, D-serine dodecylamide or D-alanine dodecylamide.
15. (withdrawn): The method of claim 1 or 9 wherein the agent is used in combination with typical or atypical antipsychotics administered orally, parenterally or by depot formulation.
16. (withdrawn): The method of claim 1 or 9 wherein the agent is used in combination with other treatments commonly used in schizophrenia, including but not limited to antidepressants, mood stabilizers, or antianxiety agents.
17. (withdrawn): The method of claim 1 or 9 wherein the agent is used in combination with a glycine transport inhibitor.

18. (currently amended): A composition for treating schizophrenia comprising an effective amount of a selective D-serine transport inhibitor as the active ingredient and a pharmaceutically acceptable carrier.

19. (currently amended): ~~A~~ The composition of claim 18, wherein the inhibitor is ~~glycyl dodecylamide, D-serine dodecylamide or D-alanine dodecylamide.~~

20. (currently amended): ~~A~~ The composition of claim 18 wherein the inhibitor is a ~~derivative of serine or alanine~~ compound having effectiveness in inhibiting D-serine transport in vivo.

21. (currently amended): ~~A~~ The composition of claim 18 wherein the D-serine transport inhibitor is present in an amount sufficient to augment NMDA-mediated neurotransmission and is combined with a typical or atypical antipsychotic agent administerable orally or parenterally.

22. (currently amended): ~~A~~ The composition of claim 20 wherein the ~~derivative is a hydrophobic derivative of serine or alanine~~ inhibitor compound comprises a hydrophobic group.

23. (currently amended): The ~~A~~ composition of claim 22 wherein the ~~derivative is serine or alanine having a hydrophobic group~~ is linked to at least one of the C- and N-terminus of the serine or alanine inhibitor compound.

24. (currently amended): ~~A~~ The composition of claim 22 where the hydrophobic group is selected from the group consisting of a C1-C13 alkyl (C1-C13) group, an unsubstituted or substituted phenyl group, a C1-C13 phenylalkyl (C1-C13) group, a cyano group, a halogen group and a C1-C13 haloalkyl (C1-C13) group.

25. (withdrawn): A method of claim 1 wherein a composition of claim 20 is used.
26. (withdrawn): A method of claim 9 wherein a composition of claim 20 is used.